PHS
PFM Health Sciences Portfolio holdings
AUM
$1.15B
This Quarter Return
+16.19%
1 Year Return
+21.39%
3 Year Return
+130.75%
5 Year Return
+265.32%
10 Year Return
+1,236.5%
AUM
$2.01B
AUM Growth
+$2.01B
(+21%)
Cap. Flow
+$161M
Cap. Flow
% of AUM
8%
Top 10 Holdings %
Top 10 Hldgs %
42.09%
Holding
88
New
23
Increased
17
Reduced
15
Closed
3
Top Buys
| 1 |
Intuitive Surgical
ISRG
|
$34.6M |
| 2 |
Zimmer Biomet
ZBH
|
$24.8M |
| 3 |
DexCom
DXCM
|
$21.6M |
| 4 |
iShares Russell 2000 ETF
IWM
|
$20.8M |
| 5 |
West Pharmaceutical
WST
|
$20.3M |
Top Sells
| 1 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
$41.2M |
| 2 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$17.1M |
| 3 |
Day One Biopharmaceuticals
DAWN
|
$15.7M |
| 4 |
Roivant Sciences
ROIV
|
$13.6M |
| 5 |
Sana Biotechnology
SANA
|
$12.1M |
Sector Composition
| 1 | Healthcare | 95.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Molina Healthcare
MOH
$9.8B
| $28.8M | 1.35% | 70,088 | – | – |
|
27
Elevance Health
ELV
$71.8B
| $28.6M | 1.35% | 55,250 +7,569 | +16% | +$3.92M |
|
28
IQVIA
IQV
$32.4B
| $28.3M | 1.33% | 111,854 | – | – |
|
29
Veeva Systems
VEEV
$44B
| $27.5M | 1.3% | 118,905 | – | – |
|
30
ESSA Pharma
EPIX
$11.4M
| $25.3M | 1.19% | 2,980,420 -282,080 | -9% | -$2.39M |
|
|
31
DexCom
DXCM
$29.5B
| $21.6M | 1.02% | +155,878 | New | +$21.6M |
|
32
Acadia Healthcare
ACHC
$2.12B
| $21.2M | 1% | 267,734 -40,203 | -13% | -$3.18M |
|
33
Arcellx
ACLX
$3.85B
| $21.1M | 0.99% | 303,210 -31,988 | -10% | -$2.22M |
|
|
34
iShares Russell 2000 ETF
IWM
$67B
| $20.8M | 0.98% | +99,115 | New | +$20.8M |
|
|
35
West Pharmaceutical
WST
$17.8B
| $20.3M | 0.95% | +51,197 | New | +$20.3M |
|
36
Stryker
SYK
$150B
| $19.7M | 0.93% | 55,092 -3,537 | -6% | -$1.27M |
|
37
Werewolf Therapeutics
HOWL
$59.9M
| $19.5M | 0.92% | 3,006,734 -461,443 | -13% | -$2.99M |
|
|
ADAP
38
Adaptimmune Therapeutics
ADAP
$15.6M
| $16.5M | 0.77% | 10,423,135 | – | – |
|
39
Syndax Pharmaceuticals
SNDX
$1.41B
| $15.7M | 0.74% | 658,694 +63,171 | +11% | +$1.5M |
|
40
Immunovant
IMVT
$2.56B
| $15.3M | 0.72% | 472,540 | – | – |
|
41
Metagenomi
MGX
$65.3M
| $13.4M | 0.63% | +1,267,002 | New | +$13.4M |
|
42
Waters Corp
WAT
$18B
| $13.2M | 0.62% | +38,464 | New | +$13.2M |
|
43
Oscar Health
OSCR
$4.31B
| $12.8M | 0.6% | 860,821 +524,655 | +156% | +$7.8M |
|
44
ARK Innovation ETF
ARKK
$7.45B
| $12.1M | 0.57% | +242,260 | New | +$12.1M |
|
45
Boston Scientific
BSX
$156B
| $11.8M | 0.56% | 172,786 -65,350 | -27% | -$4.48M |
|
46
Alkermes
ALKS
$4.78B
| $11.6M | 0.55% | +429,573 | New | +$11.6M |
|
47
Celcuity
CELC
$2.17B
| $10.7M | 0.5% | 497,002 +340,005 | +217% | +$7.34M |
|
48
UnitedHealth
UNH
$281B
| $9.58M | 0.45% | 19,361 | – | – |
|
|
CMPS
49
Compass Pathways
CMPS
$424M
| $9.07M | 0.43% | 1,089,592 +750,831 | +222% | +$6.25M |
|
50
Madrigal Pharmaceuticals
MDGL
$9.76B
| $8M | 0.38% | +29,973 | New | +$8M |
|